Related references
Note: Only part of the references are listed.Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
Melanie B. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis
Christophe Moreno et al.
JOURNAL OF HEPATOLOGY (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas et al.
NATURE (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
Alessandra Mangia et al.
HEPATOLOGY (2008)
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1
Ira M. Jacobson et al.
HEPATOLOGY (2007)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
Hari S. Conjeevaram et al.
GASTROENTEROLOGY (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
DM Jensen et al.
HEPATOLOGY (2006)
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
S Zeuzem et al.
JOURNAL OF HEPATOLOGY (2006)
Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1
LJ Jeffers et al.
HEPATOLOGY (2004)
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
AJ Muir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status
AM Di Bisceglie et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
